
Investments
94Portfolio Exits
19Funds
6Service Providers
1About Decheng Capital
Decheng Capital is an investment firm that provides capital and strategic support to early-stage life science companies with innovative technologies and growth-stage healthcare companies.

Want to inform investors similar to Decheng Capital about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Decheng Capital News
Sep 8, 2023
Grit Biotechnology , a Shanghai, China-based cell therapy company, raised $60M in Series B funding. The round was led by CICC with participation from Qianhai Ark, Liando Group, Yuanhe Capital, HeFangTian Venture Partnership and existing investors Sherpa Healthcare Partners, Decheng Capital and Matrix Partners China. The company intends to use the funds to support its Tumor-Infiltrating Lymphocyte (TIL) pipeline development, including the pivotal Phase II trial for GT101 and the advancement of gene-edited TIL products. Founded in 2019, Grit Biotechnology is a cell therapy company focused on delivering transformative cancer treatments. GT101 is currently the fastest-developing TIL therapy in China and will enter a Phase II trial by the end of 2023. The company has four core technology platforms central to its TIL development: StemTexp®, StaViral®, KOReTIL® and ImmuT Finder®, a genome-wide CRISPR/Cas9 screening platform. GT201, a genetically engineered TIL product by Grit Biotechnology, boosts T cell survival and function by expressing a vital membrane-bound cytokine. It surpasses traditional TIL therapies in proliferation, tumor-killing and persistence with reduced reliance on IL-2. GT201 IND is approved by CFDA and entered Phase I clinical trials. GT316, its TIL product, enhances TIL performance through knock-out of immunoregulatory targets identified via ImmuT Finder® CRISPR/Cas9 screening. In PDX mouse models, GT316 effectively eliminates tumors supported by low-dose IL-2 support with minimal toxicity. It offers substantial clinical benefits compared to conventional TIL products and is currently in IIT clinical trials in China. FinSMEs 08/09/2023
Decheng Capital Investments
94 Investments
Decheng Capital has made 94 investments. Their latest investment was in Cellares as part of their Series C on August 8, 2023.

Decheng Capital Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/23/2023 | Series C | Cellares | $255M | No | 6 | |
8/2/2023 | Series E - II | CG Oncology | $105M | No | 4 | |
6/8/2023 | Series B | Upstream Bio | $200M | No | 5 | |
4/11/2023 | Series A | |||||
2/14/2023 | Series A |
Date | 8/23/2023 | 8/2/2023 | 6/8/2023 | 4/11/2023 | 2/14/2023 |
---|---|---|---|---|---|
Round | Series C | Series E - II | Series B | Series A | Series A |
Company | Cellares | CG Oncology | Upstream Bio | ||
Amount | $255M | $105M | $200M | ||
New? | No | No | No | ||
Co-Investors | |||||
Sources | 6 | 4 | 5 |
Decheng Capital Portfolio Exits
19 Portfolio Exits
Decheng Capital has 19 portfolio exits. Their latest portfolio exit was Acelyrin on May 05, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/5/2023 | IPO | Public | 5 | ||
9/8/2022 | Asset Sale | 2 | |||
8/1/2022 | Reverse Merger | 3 | |||
Date | 5/5/2023 | 9/8/2022 | 8/1/2022 | ||
---|---|---|---|---|---|
Exit | IPO | Asset Sale | Reverse Merger | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 5 | 2 | 3 |
Decheng Capital Fund History
6 Fund Histories
Decheng Capital has 6 funds, including Decheng Capital China Life Sciences USD Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
12/31/2015 | Decheng Capital China Life Sciences USD Fund II | Multi-Stage Venture Capital | Closed | 2 | |
6/6/2013 | Decheng Capital China Life Sciences USD Fund I LP | ||||
Decheng Capital China Life Sciences RMB Fund I | |||||
Decheng Investment Fund | |||||
Decheng Capital Global Life Sciences Fund IV |
Closing Date | 12/31/2015 | 6/6/2013 | |||
---|---|---|---|---|---|
Fund | Decheng Capital China Life Sciences USD Fund II | Decheng Capital China Life Sciences USD Fund I LP | Decheng Capital China Life Sciences RMB Fund I | Decheng Investment Fund | Decheng Capital Global Life Sciences Fund IV |
Fund Type | Multi-Stage Venture Capital | ||||
Status | Closed | ||||
Amount | |||||
Sources | 2 |
Decheng Capital Service Providers
1 Service Provider
Decheng Capital has 1 service provider relationship
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
Counsel | General Counsel |
Service Provider | |
---|---|
Associated Rounds | |
Provider Type | Counsel |
Service Type | General Counsel |
Partnership data by VentureSource
Decheng Capital Team
3 Team Members
Decheng Capital has 3 team members, including current Founder, Managing Director, Min Cui.
Name | Work History | Title | Status |
---|---|---|---|
Min Cui | Founder, Managing Director | Current | |
Name | Min Cui | ||
---|---|---|---|
Work History | |||
Title | Founder, Managing Director | ||
Status | Current |